Nice_老虎社区_美港股上老虎

2021-09-23

Nice

AstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs<blockquote>阿斯利康投资帝国理工学院自扩增RNA技术着眼于未来药物</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":863849667,"tweetId":"863849667","gmtCreate":1632377458159,"gmtModify":1632800795368,"author":{"id":3568542354994015,"idStr":"3568542354994015","authorId":3568542354994015,"authorIdStr":"3568542354994015","name":"咩咩虎","avatar":"https://static.tigerbbs.com/a6663bef57eca539a2c52ea184964654","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":17,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Nice&nbsp;</body></html>","htmlText":"<html><head></head><body>Nice&nbsp;</body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/863849667","repostId":1158262650,"repostType":4,"repost":{"id":"1158262650","kind":"news","pubTimestamp":1632377121,"share":"https://www.laohu8.com/m/news/1158262650?lang=zh_CN&edition=full","pubTime":"2021-09-23 14:05","market":"us","language":"en","title":"AstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs<blockquote>阿斯利康投资帝国理工学院自扩增RNA技术着眼于未来药物</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1158262650","media":"Reuters","summary":"LONDON, Sept 23 (Reuters) - AstraZeneca Plc on Thursday struck a deal with the firm behind Imperial ","content":"LONDON, Sept 23 (Reuters) - AstraZeneca Plc on Thursday struck a deal with the firm behind Imperial College London’s experimental COVID-19 vaccine to develop and sell drugs based on its self-amplifying RNA technology platform in other disease areas.<blockquote>路透伦敦9月23日-阿斯利康公司周四与伦敦帝国理工学院实验性COVID-19疫苗背后的公司达成协议，在其他疾病领域开发和销售基于其自扩增RNA技术平台的药物。</blockquote> Under the deal, VaxEquity, a startup founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met, in addition to royalties on approved drugs and equity investment from AstraZeneca and life sciences investor Morningside Ventures.<blockquote>根据协议，由帝国疫苗学家Robin Shattock创立的初创公司VaxEquity如果达到某些里程碑，除了获得批准药物的特许权使用费以及阿斯利康和生命科学投资者Morningside Ventures的股权投资外，还可以获得高达1.95亿美元的资金。</blockquote> AstraZeneca already produces an adenoviral vector COVID-19 vaccine, and emphasised the potential of the self-amplifying RNA (saRNA) technology in novel therapeutic programmes beyond the coronavirus pandemic.<blockquote>阿斯利康已经生产了腺病毒载体新冠肺炎疫苗，并强调了自扩增RNA（saRNA）技术在冠状病毒疫情以外的新型治疗项目中的潜力。</blockquote> “This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox,” said AstraZeneca research chief Mene Pangalos.<blockquote>阿斯利康研究主管Mene Pangalos表示：“与VaxEquity的合作为我们的药物发现工具箱增加了一个有前途的新平台。”</blockquote> The technology works in a similar way to the messenger RNA (mRNA) vaccines made by Pfizer/BioNTech and Moderna.<blockquote>该技术的工作方式类似于辉瑞/BioNTech和Moderna生产的信使RNA（mRNA）疫苗。</blockquote> However, a self-amplifying RNA vaccine not only encodes the instructions for the host cell to make a coronavirus protein, but makes lots of copies of the RNA containing those instructions, meaning doses can be smaller and cheaper.<blockquote>然而，自扩增RNA疫苗不仅编码宿主细胞制造冠状病毒蛋白的指令，还会制造大量含有这些指令的RNA拷贝，这意味着剂量可以更小、更便宜。</blockquote> “It’s a bit like having a manufacturing facility, and instead of having one copy of the recipe, you have multiple copies that you can hand round to multiple production lines within the cell to produce more protein,” Imperial’s Shattock told Reuters. “So that’s why it has that opportunity to use lower doses.”<blockquote>帝国理工学院的沙托克告诉路透社：“这有点像拥有一个制造设施，你不是只有一份食谱，而是有多份副本，可以将它们分发给细胞内的多条生产线以生产更多蛋白质。”“所以这就是为什么它有机会使用较低剂量。”</blockquote> Imperial’s COVID-19 vaccine is being retooled to produce a more consistent immune response with an eye on future coronavirus variants.<blockquote>帝国理工学院的新冠肺炎疫苗正在重组，以产生更一致的免疫反应，着眼于未来的冠状病毒变种。</blockquote> AstraZeneca, under the deal, has the option to collaborate on 26 drug targets for use against other therapeutic areas like cancers and rare genetic diseases.<blockquote>根据协议，阿斯利康可以选择在26个药物靶点上进行合作，用于治疗癌症和罕见遗传疾病等其他治疗领域。</blockquote> “We believe self-amplifying RNA, once optimised, will allow us to target novel pathways not amenable to traditional drug discovery across our therapy areas of interest,” Pangalos said.<blockquote>Pangalos说：“我们相信，自扩增RNA一旦得到优化，将使我们能够在我们感兴趣的治疗领域瞄准不适合传统药物发现的新途径。”</blockquote> U.S. companies Gritstone bio and Arcturus also are developing saRNA COVID-19 vaccines.<blockquote>美国公司Gritstone bio和Arcturus也在开发saRNA COVID-19疫苗。</blockquote> Shattock said safety data had been encouraging from initial trials of its COVID-19 vaccine, released in July ahead of peer review, and that Phase I results of its refined vaccine would be ready early next year.<blockquote>Shattock表示，其COVID-19疫苗的初步试验的安全数据令人鼓舞，该疫苗于7月在同行评审之前发布，其改进疫苗的第一阶段结果将于明年初准备就绪。</blockquote> “The reason we were slower was because we were coming from an academic setting,” he said. “If we had this relationship (with AstraZeneca) at the beginning of 2020, we might have been faster.”<blockquote>“我们速度较慢的原因是因为我们来自学术环境，”他说。“如果我们在2020年初（与阿斯利康）有这种关系，我们可能会更快。”</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs<blockquote>阿斯利康投资帝国理工学院自扩增RNA技术着眼于未来药物</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs<blockquote>阿斯利康投资帝国理工学院自扩增RNA技术着眼于未来药物</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nReuters2021-09-23 14:05\n\n</h4>\n</header>\n<article>\nLONDON, Sept 23 (Reuters) - AstraZeneca Plc on Thursday struck a deal with the firm behind Imperial College London’s experimental COVID-19 vaccine to develop and sell drugs based on its self-amplifying RNA technology platform in other disease areas.<blockquote>路透伦敦9月23日-阿斯利康公司周四与伦敦帝国理工学院实验性COVID-19疫苗背后的公司达成协议，在其他疾病领域开发和销售基于其自扩增RNA技术平台的药物。</blockquote> Under the deal, VaxEquity, a startup founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met, in addition to royalties on approved drugs and equity investment from AstraZeneca and life sciences investor Morningside Ventures.<blockquote>根据协议，由帝国疫苗学家Robin Shattock创立的初创公司VaxEquity如果达到某些里程碑，除了获得批准药物的特许权使用费以及阿斯利康和生命科学投资者Morningside Ventures的股权投资外，还可以获得高达1.95亿美元的资金。</blockquote> AstraZeneca already produces an adenoviral vector COVID-19 vaccine, and emphasised the potential of the self-amplifying RNA (saRNA) technology in novel therapeutic programmes beyond the coronavirus pandemic.<blockquote>阿斯利康已经生产了腺病毒载体新冠肺炎疫苗，并强调了自扩增RNA（saRNA）技术在冠状病毒疫情以外的新型治疗项目中的潜力。</blockquote> “This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox,” said AstraZeneca research chief Mene Pangalos.<blockquote>阿斯利康研究主管Mene Pangalos表示：“与VaxEquity的合作为我们的药物发现工具箱增加了一个有前途的新平台。”</blockquote> The technology works in a similar way to the messenger RNA (mRNA) vaccines made by Pfizer/BioNTech and Moderna.<blockquote>该技术的工作方式类似于辉瑞/BioNTech和Moderna生产的信使RNA（mRNA）疫苗。</blockquote> However, a self-amplifying RNA vaccine not only encodes the instructions for the host cell to make a coronavirus protein, but makes lots of copies of the RNA containing those instructions, meaning doses can be smaller and cheaper.<blockquote>然而，自扩增RNA疫苗不仅编码宿主细胞制造冠状病毒蛋白的指令，还会制造大量含有这些指令的RNA拷贝，这意味着剂量可以更小、更便宜。</blockquote> “It’s a bit like having a manufacturing facility, and instead of having one copy of the recipe, you have multiple copies that you can hand round to multiple production lines within the cell to produce more protein,” Imperial’s Shattock told Reuters. “So that’s why it has that opportunity to use lower doses.”<blockquote>帝国理工学院的沙托克告诉路透社：“这有点像拥有一个制造设施，你不是只有一份食谱，而是有多份副本，可以将它们分发给细胞内的多条生产线以生产更多蛋白质。”“所以这就是为什么它有机会使用较低剂量。”</blockquote> Imperial’s COVID-19 vaccine is being retooled to produce a more consistent immune response with an eye on future coronavirus variants.<blockquote>帝国理工学院的新冠肺炎疫苗正在重组，以产生更一致的免疫反应，着眼于未来的冠状病毒变种。</blockquote> AstraZeneca, under the deal, has the option to collaborate on 26 drug targets for use against other therapeutic areas like cancers and rare genetic diseases.<blockquote>根据协议，阿斯利康可以选择在26个药物靶点上进行合作，用于治疗癌症和罕见遗传疾病等其他治疗领域。</blockquote> “We believe self-amplifying RNA, once optimised, will allow us to target novel pathways not amenable to traditional drug discovery across our therapy areas of interest,” Pangalos said.<blockquote>Pangalos说：“我们相信，自扩增RNA一旦得到优化，将使我们能够在我们感兴趣的治疗领域瞄准不适合传统药物发现的新途径。”</blockquote> U.S. companies Gritstone bio and Arcturus also are developing saRNA COVID-19 vaccines.<blockquote>美国公司Gritstone bio和Arcturus也在开发saRNA COVID-19疫苗。</blockquote> Shattock said safety data had been encouraging from initial trials of its COVID-19 vaccine, released in July ahead of peer review, and that Phase I results of its refined vaccine would be ready early next year.<blockquote>Shattock表示，其COVID-19疫苗的初步试验的安全数据令人鼓舞，该疫苗于7月在同行评审之前发布，其改进疫苗的第一阶段结果将于明年初准备就绪。</blockquote> “The reason we were slower was because we were coming from an academic setting,” he said. “If we had this relationship (with AstraZeneca) at the beginning of 2020, we might have been faster.”<blockquote>“我们速度较慢的原因是因为我们来自学术环境，”他说。“如果我们在2020年初（与阿斯利康）有这种关系，我们可能会更快。”</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/article/health-coronavirus-astrazeneca-imperial/astrazeneca-invests-in-imperials-self-amplifying-rna-technology-with-eye-on-future-drugs-idUSL8N2QO4JM\">Reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"https://www.reuters.com/article/health-coronavirus-astrazeneca-imperial/astrazeneca-invests-in-imperials-self-amplifying-rna-technology-with-eye-on-future-drugs-idUSL8N2QO4JM","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158262650","content_text":"LONDON, Sept 23 (Reuters) - AstraZeneca Plc on Thursday struck a deal with the firm behind Imperial College London’s experimental COVID-19 vaccine to develop and sell drugs based on its self-amplifying RNA technology platform in other disease areas.\nUnder the deal, VaxEquity, a startup founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met, in addition to royalties on approved drugs and equity investment from AstraZeneca and life sciences investor Morningside Ventures.\nAstraZeneca already produces an adenoviral vector COVID-19 vaccine, and emphasised the potential of the self-amplifying RNA (saRNA) technology in novel therapeutic programmes beyond the coronavirus pandemic.\n“This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox,” said AstraZeneca research chief Mene Pangalos.\nThe technology works in a similar way to the messenger RNA (mRNA) vaccines made by Pfizer/BioNTech and Moderna.\nHowever, a self-amplifying RNA vaccine not only encodes the instructions for the host cell to make a coronavirus protein, but makes lots of copies of the RNA containing those instructions, meaning doses can be smaller and cheaper.\n“It’s a bit like having a manufacturing facility, and instead of having one copy of the recipe, you have multiple copies that you can hand round to multiple production lines within the cell to produce more protein,” Imperial’s Shattock told Reuters. “So that’s why it has that opportunity to use lower doses.”\nImperial’s COVID-19 vaccine is being retooled to produce a more consistent immune response with an eye on future coronavirus variants.\nAstraZeneca, under the deal, has the option to collaborate on 26 drug targets for use against other therapeutic areas like cancers and rare genetic diseases.\n“We believe self-amplifying RNA, once optimised, will allow us to target novel pathways not amenable to traditional drug discovery across our therapy areas of interest,” Pangalos said.\nU.S. companies Gritstone bio and Arcturus also are developing saRNA COVID-19 vaccines.\nShattock said safety data had been encouraging from initial trials of its COVID-19 vaccine, released in July ahead of peer review, and that Phase I results of its refined vaccine would be ready early next year.\n“The reason we were slower was because we were coming from an academic setting,” he said. “If we had this relationship (with AstraZeneca) at the beginning of 2020, we might have been faster.”","news_type":1,"symbols_score_info":{"AZN":0.9}},"isVote":1,"tweetType":1,"viewCount":401,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/863849667"}